

# NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

## Diagnostics Advisory Committee (DAC)

### Minutes of the Meeting on Tuesday, 20 June 2017

Level 1A City Tower, Piccadilly Plaza, Manchester M1 4BD

#### **PRESENT:**

##### **Standing Committee members:**

Dr Mark Kroese (Chair)  
Mrs Alexandria Moseley  
Professor Anthony Wierzbicki  
Professor Christopher Hyde  
Dr Dermot Neely  
Professor Enitan Carrol  
Dr Jim Gray  
Mr John Bagshaw  
Dr Michael Messenger  
Dr Owen Driskell  
Mr Patrick McGinley  
Dr Peter Naylor  
Dr Simon Fleming  
Dr Steve Edwards

##### **Standing Committee apologies:**

Professor Adrian Newland  
Mr John Hitchman  
Professor Mark Sculpher  
Professor Matt Stevenson  
Dr Simon Richards  
Professor Steve Halligan  
Dr Sue Crawford

##### **NICE staff in attendance:**

Mark Campbell, Associate Director, Medical Technologies Evaluation Programme  
Thomas Walker, (Technical lead) Technical Analyst, DAP  
Frances Nixon, Technical Adviser, DAP  
Robert Fernley, Project Manager, DAP  
Nick Lowe, Administrator, DAP

##### **Observing:**

Elaine Chesworth, Medical Technology Implementation Manager  
Ian Mather, Business Analyst  
Lydia Shears, Public Involvement Adviser

**1. Introduction to the meeting**

The Chair welcomed Committee members, observers and members of the public.

Apologies were noted.

**2. Code of conduct for members of the public attending the meeting**

The Chair explained the code of conduct to the members of the public attending this meeting.

**3. Any other business**

No other business was offered.

**4. Minutes from the last Committee meeting**

The Committee agreed the minutes from the 23 March 2017 Committee meeting.

**5. NICE's advisory body guide to declaring a conflict of interest**

The Chair drew the Committee's attention to NICE's Advisory Body Quick Guide for declaring conflicts of interest, the selection and routing criteria and the equalities statement.

**Tests in secondary care to identify people at high risk of ovarian cancer**

**External Assessment Group representatives: Kleijnen Systematic Reviews Ltd**

Dr Bram Ramaekers, Health Economist  
Dr Marie Westwood, Review Manager  
Sabine Grimm, Health Economist

**Specialist Committee members:**

Dr Cathie Sturgeon, Consultant Clinical Scientist  
Dr Hilary Morrison, Lay Specialist Committee Member  
Mr Jed Hawe, Consultant Gynaecologist  
Dr Jurjees Hasan, Consultant Medical Oncologist  
Dr Michael Weston, Consultants Radiologist  
Professor Richard Edmondson, Professor of Gynaecological Oncology  
Mr Stuart Morgan, Lay Specialist Committee Member  
Dr Sudha Sundar, Senior Lecturer & Consultant in Gynaecological Oncology  
Dr Tracie Miles, Clinical Nurse Specialist

**Specialist Committee member apologies:**

None

## **PART 1 AND PART 2 (open and closed parts of the meeting).**

### **Part 1 – Open session**

The Chair welcomed representatives from Abbott Laboratories, Fujirebio Diagnostics AB, International Ovarian Tumor Analysis Group (IOTA) and Roche Diagnostics Ltd.

There were 3 public attendees.

The Chair asked Committee members to declare any relevant interests.

- Professor Mark Sculpher declared a personal specific interest; this meant he was unable to take part in the meeting.
- Simon Richards declared a personal specific financial interest; this meant he was unable to take part in the meeting.

The Committee proceeded to discuss the clinical effectiveness and cost effectiveness of tests in secondary care to identify people at high risk of ovarian cancer.

The Committee was asked if there were any specific equality issues to consider in relation to this assessment.

The Chair asked the representatives of the manufacturers whether they wished to comment on any matters of factual accuracy.

The Chair explained that “representatives of the press and other members of the public be excluded from the remainder of this meeting having regard to the confidential nature of the business to be transacted, publicity on which would be prejudicial to the public interest” (Section 1(2) Public Bodies (Admission to Meetings) Act 1960)” and all public attendees left the meeting.

The Chair thanked the manufacturer representatives for their attendance, participation and contribution to the meeting.

### **End of Part 1**

### **Part 2 – closed session**

Agreement on the content of the Diagnostic Consultation Document (DCD) was discussed by the committee.

### **End of Part 2**

### **Date, time and venue of next meeting**

**Thursday, 27 July 2017** at Mercure Manchester Piccadilly Hotel, Portland Street, Manchester, M1 4PH,